Galera Therapeutics, Inc.
Galera Therapeutics, Inc. (GRTX) filed an SEC Form 8-K — Completion of Acquisition or Disposition of Assets. EX-10.1 4 d170816dex101.htm EX-10.1 EX-10.1 Exhibit 10.1 CONTINGENT VALUE RIGHTS AGREEMENT THIS CONTINGENT VALUE RIGHTS AGREEMENT, dated as of July 31, 2026 (this “ Agreement ”), is entered into by and between GAZELLE PARENT, INC., a Delaware corporation (“ Parent ”), OBSIDIAN TH
Galera Therapeutics, Inc. (GRTX) filed an SEC Form 8-K — Unregistered Sales of Equity Securities. 8-K NASDAQ false 0001563577 0001563577 2026-07-31 2026-07-31 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): Ju
Over the past 7 days, alphai's AI scored 1 news story mentioning GRTX (Galera Therapeutics, Inc.). Coverage has been balanced: 0 bullish, 1 neutral, and 0 bearish.
Recent GRTX coverage spans mergers & acquisitions and corporate actions.
In the last 30 days, GRTX insiders filed 5 SEC Form 4 transactions — no purchases and 5 sales. The most active reporter was Alleva Lawrence M with 2 filings.
The CVR structure implies additional, contingent cash payments to GRTX holders based on future net proceeds from specified product agreements, affecting valuation and post-close trading.
Financing completion plus a near-term merger close date can reprice deal-risk and liquidity expectations for GRTX.
alphai scores every news story that mentions GRTX with an AI model for sentiment and relevance, and aggregates insider trades from Galera Therapeutics, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Galera Therapeutics, Inc. (GRTX) filed an SEC Form 8-K — Completion of Acquisition or Disposition of Assets. EX-10.1 4 d170816dex101.htm EX-10.1 EX-10.1 Exhibit 10.1 CONTINGENT VALUE RIGHTS AGREEMENT THIS CONTINGENT VALUE RIGHTS AGREEMENT, dated as of July 31, 2026 (this “ Agreement ”), is entered into by and between GAZELLE PARENT, INC., a Delaware corporation (“ Parent ”), OBSIDIAN TH
4 min readGalera Therapeutics, Inc. (GRTX) filed an SEC Form 8-K — Unregistered Sales of Equity Securities. 8-K NASDAQ false 0001563577 0001563577 2026-07-31 2026-07-31 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): Ju
4 min read